Angiopoietin-1 but not angiopoietin-2 induces IL-8 synthesis and release by human neutrophils.
We previously reported Tie2 receptor expression on human neutrophils, which promote chemotactic activities upon activation by both angiopoietins (Ang1 and Ang2). Moreover, we observed that neutrophil pretreatment with Ang1 or Ang2 enhances interleukin-8 (IL-8) chemotactic effect. Therefore, we assessed the capacity of Ang1 and/or Ang2 to modulate neutrophil IL-8 synthesis and release. Neutrophils isolated from healthy donors were stimulated in a time- (1-6 h) and concentration-(10(-10) -10(-8)  M) dependent manner with both angiopoietins. IL-8 mRNA production was measured by RT-qPCR, whereas its protein synthesis and release from neutrophils was assessed by ELISA. Ang1 (10(-8)  M) induced a significant and maximal increase of IL-8 mRNA (4.7-fold) within 1 h, and promoted maximal IL-8 protein synthesis (3.6-fold) and release (5.5-fold) within 2 h as compared to control PBS-treated neutrophils. Treatment with Ang2 alone did not modulate IL-8 synthesis or release, and its combination to Ang1 did not affect Ang1 activity. Neutrophil pretreatment with a protein synthesis inhibitor (CHX) increased IL-8 mRNA synthesis by 18-fold, and reduced Ang1-mediated IL-8 protein synthesis and release by 96% and 92%, respectively. Pretreatment with a transcription inhibitor (ActD) reduced IL-8 mRNA synthesis by 54% and IL-8 protein synthesis and release by 52% and 79%, respectively. Using specific kinase inhibitors, we observed that Ang1-driven IL-8 mRNA and protein synthesis is p42/44 MAPK-dependent and -independent from p38 MAPK and PI3K activity. Our study is the first to report the capacity of Ang1 (as opposed to Ang2) to promote neutrophil IL-8 synthesis and release through the activation of p42/44 MAPK pathway.
Research Center, Montreal Heart Institute, Faculty of Medicine, Université de Montréal, Montreal, Quebec, Canada.
Paul-Eduard
PE
Neagoe
Elizabeth
E
Dumas
Fadi
F
Hajjar
Martin G
MG
Sirois
D042683:Angiopoietin-1 / Q000008:administration & dosage / Q000378:metabolism*; D042702:Angiopoietin-2 / Q000008:administration & dosage / Q000378:metabolism*; D003609:Dactinomycin / Q000494:pharmacology; D005786:Gene Expression Regulation / Q000187:drug effects; D006801:Humans; D016209:Interleukin-8 / Q000096:biosynthesis* / Q000378:metabolism; D019950:Mitogen-Activated Protein Kinase 1 / Q000378:metabolism; D048052:Mitogen-Activated Protein Kinase 3 / Q000378:metabolism; D009504:Neutrophils / Q000378:metabolism*; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism; D011500:Protein Synthesis Inhibitors / Q000494:pharmacology; D012333:RNA, Messenger / Q000378:metabolism*; D015398:Signal Transduction; D048051:p38 Mitogen-Activated Protein Kinases / Q000378:metabolism
D042683:Angiopoietin-1; D042702:Angiopoietin-2; D016209:Interleukin-8; D011500:Protein Synthesis Inhibitors; D012333:RNA, Messenger; D003609:Dactinomycin; D019869:Phosphatidylinositol 3-Kinases; D019950:Mitogen-Activated Protein Kinase 1; D048052:Mitogen-Activated Protein Kinase 3; D048051:p38 Mitogen-Activated Protein Kinases